Cargando…

Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology

Gaucher disease (GD) is caused by insufficient activity of acid β-glucosidase (GCase) resulting from mutations in GBA1. To understand the pathogenesis of the neuronopathic GD, induced pluripotent stem cells (iPSCs) were generated from fibroblasts isolated from three GD type 2 (GD2) and 2 unaffected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Ying, Florer, Jane, Mayhew, Christopher N., Jia, Zhanfeng, Zhao, Zhiying, Xu, Kui, Ran, Huimin, Liou, Benjamin, Zhang, Wujuan, Setchell, Kenneth D. R., Gu, Jianguo, Grabowski, Gregory A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378893/ https://www.ncbi.nlm.nih.gov/pubmed/25822147 http://dx.doi.org/10.1371/journal.pone.0118771

Ejemplares similares

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Substrate Compositional Variation with Tissue/Region and Gba1 Mutations in Mouse Models–Implications for Gaucher Disease
por: Sun, Ying, et al.
Publicado: (2013)

Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014)

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease
por: Peng, Yanyan, et al.
Publicado: (2021)

Global gene expression profile progression in Gaucher disease mouse models
por: Xu, You-Hai, et al.
Publicado: (2011)

Combination of acid β-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype
por: Liou, Benjamin, et al.
Publicado: (2019)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease
por: Dai, Mei, et al.
Publicado: (2016)

In Vivo and Ex Vivo Evaluation of L-Type Calcium Channel Blockers on Acid β-Glucosidase in Gaucher Disease Mouse Models
por: Sun, Ying, et al.
Publicado: (2009)

Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases
por: Zhao, Xiangli, et al.
Publicado: (2022)

Leptomeninges-Derived Induced Pluripotent Stem Cells and Directly Converted Neurons From Autopsy Cases With Varying Neuropathologic Backgrounds
por: Rose, Shannon E, et al.
Publicado: (2018)

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
por: Sun, Ying, et al.
Publicado: (2010)

Gaucher-Associated Parkinsonism
por: Li, Yaqiong, et al.
Publicado: (2015)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
por: Sun, Ying, et al.
Publicado: (2020)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Hepatoprotectant Ursodeoxycholyl Lysophosphatidylethanolamide Increasing Phosphatidylcholine Levels as a Potential Therapy of Acute Liver Injury
por: Chamulitrat, Walee, et al.
Publicado: (2012)

Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency
por: Zhao, Xueheng, et al.
Publicado: (2022)

Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
por: Xu, You-Hai, et al.
Publicado: (2010)

Association Between Progranulin and Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

A case of motor neuron involvement in Gaucher disease
por: Pozzilli, V., et al.
Publicado: (2019)

Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned?
por: Santos, Dino Matias, et al.
Publicado: (2017)

Activation of p38 Mitogen-Activated Protein Kinase in Gaucher’s Disease
por: Kitatani, Kazuyuki, et al.
Publicado: (2015)

Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1
por: Srikanth, Manasa P., et al.
Publicado: (2021)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

White matter neuron biology and neuropathology in schizophrenia
por: Duchatel, Ryan J., et al.
Publicado: (2019)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease
por: Maas, M., et al.
Publicado: (2008)

Synthetic mRNA‐based differentiation method enables early detection of Parkinson's phenotypes in neurons derived from Gaucher disease‐induced pluripotent stem cells
por: Akiyama, Tomohiko, et al.
Publicado: (2020)

Successful treatment of infantile oxysterol 7α-hydroxylase deficiency with oral chenodeoxycholic acid
por: Tang, Yun-Ping, et al.
Publicado: (2021)

PSEN1 E280A Cholinergic-like Neurons and Cerebral Spheroids Derived from Mesenchymal Stromal Cells and from Induced Pluripotent Stem Cells Are Neuropathologically Equivalent
por: Mendivil-Perez, Miguel, et al.
Publicado: (2023)

Magnesium Is a Key Player in Neuronal Maturation and Neuropathology
por: Yamanaka, Ryu, et al.
Publicado: (2019)

Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2018)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Gaucher disease: an update
por: Dumitrascu, Dan L.
Publicado: (2021)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
por: Symeonidis, Argiris, et al.
Publicado: (2023)

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9vrvrlen500jc7ps3tc701c3pr